← All trials
NCT04697511
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 11, 2021
- Primary completion
- Feb 25, 2021
- Completion date
- Feb 25, 2021
- First posted
- Jan 6, 2021
- Last posted
- Mar 23, 2021
- Enrollment
- 16
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Merck KGaALead sponsor
- Merck KGaAStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.